Improving antibiotic treatment for resistant bloodstream infections
Part of Blood & lymphatic, Infections clinical trials.
This trial aims to improve how antibiotics are chosen for patients with resistant bacterial infections in the blood. It uses faster diagnostic tests and expert advice to ensure the most effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed bloodstream infection caused by a multidrug-resistant bacteria (a 'superbug').
- The infection is resistant to common strong antibiotics like ceftriaxone or meropenem.
- You are currently experiencing signs of infection (like fever or chills), not just a lab finding.
- The infection is caused by only one type of bacteria, not a mix.
- You are able to sign a consent form yourself or have a family member or guardian sign for you.
- You have no known severe allergies to penicillin-like antibiotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study looks at how doctors can best manage antibiotics for a common type of blood infection (caused by Enterobacterales bacteria like E. coli). If you join, your treatment will be carefully guided to make sure you get the right antibiotics at the right time, which may help you recover faster and prevent antibiotic resistance.
This trial tests whether switching from IV to oral antibiotics is just as effective for treating Gram-negative bloodstream infections. If you qualify, you may receive either continued IV antibiotics or switch to pills, with follow-up on your recovery and quality of life.
This trial tests different ways to treat infections in the blood caused by Gram-negative bacteria. It looks at whether reducing antibiotics, switching to pills, or managing central lines improves outcomes while keeping you safe.
This trial looks at whether a rapid molecular test can help doctors choose the right antibiotics faster for hospitalized patients. It aims to improve how antibiotics are used and reduce unnecessary side effects.
Hear when a new Bloodstream Infection Multidrug-resistant Gram-negative Bacteria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.